Format

Send to

Choose Destination
BMC Med. 2012 Aug 9;10:87. doi: 10.1186/1741-7015-10-87.

The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?

Author information

1
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada. ediamandis@mtsinai.on.ca

Abstract

There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent reports (rare); true discoveries of biomarkers, that then fail to meet the demands of the clinic; and false discoveries, which represent artifactual biomarkers. I further provide examples of combinations of some known cancer biomarkers that can perform well in niche clinical applications, despite individually being not useful.

PMID:
22876833
PMCID:
PMC3425158
DOI:
10.1186/1741-7015-10-87
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center